HSP-CAR30

CAR T-cell therapy targeting CD30 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HSP-CAR30, covering 2020-12-04 to 2020-12-04. Get the full timeline:

Most recent: Clinical Trial Update: CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. [Phase 1, Phase 2]